Acinetobacter Baumannii Infection Clinical Trial
Official title:
Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection
Verified date | August 2016 |
Source | Southeast University, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Ethics Committee |
Study type | Observational |
The purpose of the present study is to evaluate the effects of immune function on prognositic outcome in critical ill patients with Acinetobacter baumannii infection.
Status | Completed |
Enrollment | 40 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients admitted to ICU - Infection with Acinetobacter baumannii - Agree to participate the study Exclusion Criteria: - Age less than 16 years old or older than 80 years old - pregnancy - immunosuppression patients which include 1. therapy 0.5mg/kg/day of prednisoneover(equivalent dose of other glucocorticoids) for at least 1 month within recent 3 month 2. Cancer chemotherapy within recent 3 month 3. Receive immunosuppression treatment because of solid organ transplant or Autoimmune diseases 4. allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation. 5. HIV infection |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Southeast University, China |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 28 day mortality | 28 day | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03310463 -
Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
Completed |
NCT02971423 -
Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
|
Phase 1 | |
No longer available |
NCT04636554 -
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
|